Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mitchell

Showing results (1321-1330 of 1,365) with videos related to

Pageof 137
Sort By:
Future Oncology (London, England)|June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancerLior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 SignalingThai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Medical Physics|December 19, 2024
An automated treatment planning portfolio for whole breast radiotherapyHana Baroudi, Leonard Che Fru, Deborah Schofield, et al.
Practical Radiation Oncology|December 3, 2019
Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons LearnedX Allen Li, Jennifer Moughan, Julia R White, et al.
BMJ Supportive & Palliative Care|June 6, 2024
Single-fraction radiation retreatment for bone metastases: role of a rapid access clinicMinsoo Kim, Jose Alberto Maldonado, Prasamsa Pandey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Pageof 137

Showing results (1321-1330 of 1,365) with videos related to

Sort By:
Pageof 137
Future Oncology (London, England)|June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancerLior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 SignalingThai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Medical Physics|December 19, 2024
An automated treatment planning portfolio for whole breast radiotherapyHana Baroudi, Leonard Che Fru, Deborah Schofield, et al.
Practical Radiation Oncology|December 3, 2019
Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons LearnedX Allen Li, Jennifer Moughan, Julia R White, et al.
BMJ Supportive & Palliative Care|June 6, 2024
Single-fraction radiation retreatment for bone metastases: role of a rapid access clinicMinsoo Kim, Jose Alberto Maldonado, Prasamsa Pandey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Pageof 137